198 related articles for article (PubMed ID: 37407805)
41. Multiple m
Qu N; Qin S; Zhang X; Bo X; Liu Z; Tan C; Wen G; Jiang H
BMC Cancer; 2020 Feb; 20(1):165. PubMed ID: 32111180
[TBL] [Abstract][Full Text] [Related]
42. Identification of subclusters and prognostic genes based on glycolysis/gluconeogenesis in hepatocellular carcinoma.
Chen D; Aierken A; Li H; Chen R; Ren L; Wang K
Front Immunol; 2023; 14():1232390. PubMed ID: 37881434
[TBL] [Abstract][Full Text] [Related]
43. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
44. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
Chen J; Chen X; Li T; Wang L; Lin G
Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
[TBL] [Abstract][Full Text] [Related]
45. Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis.
Zhou Z; Li Y; Hao H; Wang Y; Zhou Z; Wang Z; Chu X
Cell Transplant; 2019 Dec; 28(1_suppl):76S-86S. PubMed ID: 31822116
[TBL] [Abstract][Full Text] [Related]
46. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
[TBL] [Abstract][Full Text] [Related]
47. Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.
Chen S; Zhao E
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101587. PubMed ID: 33662631
[TBL] [Abstract][Full Text] [Related]
48. An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma.
Su Z; Wang L; Chen X; Zhong X; Wang D; Wang J; Shao L; Chen G; Wu J
Comb Chem High Throughput Screen; 2022; 25(12):2046-2058. PubMed ID: 35125080
[TBL] [Abstract][Full Text] [Related]
49. Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the importance of LDHD in the prognosis of hepatocellular carcinoma patients.
Wang S; Wu X; Wu X; Cheng J; Chen Q; Qi Z
BMC Cancer; 2024 Jan; 24(1):156. PubMed ID: 38291366
[TBL] [Abstract][Full Text] [Related]
50. DNA damage repair-related gene signature for identifying the immune status and predicting the prognosis of hepatocellular carcinoma.
Lu Y; Wang S; Chi T; Zhao Y; Guo H; Wang H; Feng L
Sci Rep; 2023 Nov; 13(1):18978. PubMed ID: 37923899
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic and prognostic values of pyroptosis-related genes for the hepatocellular carcinoma.
Xing M; Li J
BMC Bioinformatics; 2022 May; 23(1):177. PubMed ID: 35562678
[TBL] [Abstract][Full Text] [Related]
52. Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis.
Shen S; Kong J; Qiu Y; Yang X; Wang W; Yan L
J Cell Biochem; 2019 Jun; 120(6):10069-10081. PubMed ID: 30525236
[TBL] [Abstract][Full Text] [Related]
53. Weighted correlation gene network analysis reveals a new stemness index-related survival model for prognostic prediction in hepatocellular carcinoma.
Zhang Q; Wang J; Liu M; Zhu Q; Li Q; Xie C; Han C; Wang Y; Gao M; Liu J
Aging (Albany NY); 2020 Jul; 12(13):13502-13517. PubMed ID: 32644941
[TBL] [Abstract][Full Text] [Related]
54. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
Yan Z; He M; He L; Wei L; Zhang Y
Front Immunol; 2021; 12():723271. PubMed ID: 34925311
[TBL] [Abstract][Full Text] [Related]
55. Pyroptosis related genes signature predicts prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma.
Fang G; Zhang Q; Fan J; Li H; Ding Z; Fu J; Wu Y; Zeng Y; Liu J
BMC Cancer; 2022 Sep; 22(1):999. PubMed ID: 36127654
[TBL] [Abstract][Full Text] [Related]
56. Identifying hepatocellular carcinoma-related hub genes by bioinformatics analysis and CYP2C8 is a potential prognostic biomarker.
Li C; Zhou D; Jiang X; Liu M; Tang H; Mei Z
Gene; 2019 May; 698():9-18. PubMed ID: 30825595
[TBL] [Abstract][Full Text] [Related]
57. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
58. Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature.
Zhao K; Xu L; Li F; Ao J; Jiang G; Shi R; Chen F; Luo Q
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32789471
[TBL] [Abstract][Full Text] [Related]
59. Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
Xu H; Xiong C; Chen Y; Zhang C; Bai D
Bioengineered; 2021 Dec; 12(1):2664-2675. PubMed ID: 34115569
[TBL] [Abstract][Full Text] [Related]
60. A predictive and prognostic model for hepatocellular carcinoma with microvascular invasion based TCGA database genomics.
Wang J; Ding ZW; Chen K; Liu YZ; Li N; Hu MG
BMC Cancer; 2021 Dec; 21(1):1337. PubMed ID: 34911488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]